Complications of therapeutic plasma exchange
A retrospective study of 1201 procedures in 435 children

Jing Lu, MMa,b, Lijuan Zhang, MDa, Cheng Xia, MMc, Yuhong Tao, MD, PhDad,e,*

Abstract
Therapeutic plasma exchange (TPE) is now widely used in therapy of multiple diseases in children, by removing the plasma with pathogenic agents from patients. However, adverse reactions may limit its application.

A retrospective cohort study of 435 hospitalized children treated with 1201 plasma exchange procedures between January 2013 and July 2018 were enrolled.

Complications occurred in 152 procedures (12.7%); 90 procedures (7.5%) had ≥2 complications. No death occurred. The most common complications were pruritus and urticaria (7%), followed by hypertension (1.92%) and hypotension (1.17%). One child had an outbreak of disseminated cryptococcosis neoformans infection, another child developed anaphylactic shock, and 3 children presented toxic epidermal necrolysis after TPE. The incidence of pruritus and urticaria was higher in children of the 6–15 year group (P < .05) compared with other age groups. There was no significant difference in the incidence of hypertension and hypotension in children at different ages and weights (P > .05). Compared with other diseases, anti-N-methyl-D-aspartate (anti-NMDA) receptor encephalitis led to a higher incidence of complications in children (P < .05).

The results suggest that TPE is a relatively safe procedure for children, and most of the complications are mild. The most common complication is pruritus and urticaria. However, serious complications such as toxic epidermal necrolysis and infection should still be taken seriously.

Abbreviations: FFP = fresh frozen plasma, LMWH = low-molecular-weight heparin, MG = Myasthenia gravis, NMDAR = N-methyl-D-aspartate receptor, TPE = therapeutic plasma exchange.

Keywords: allergic reaction, children, complication, therapeutic plasma exchange

1. Introduction
The therapeutic plasma exchange (TPE) is a therapy in which plasma is separated from the blood cellular components ex vivo, discarded and replaced with an isosmotic fluid (commonly 5% albumin or frozen plasma) to maintain appropriate oncotic pressure in the patient. In 1960, Schwab and Fahey performed the first therapeutic plasmapheresis to reduce elevated globulin level in a patient with macroglobulinemia.[1] In 2016, clinical indications have expanded to 87 diseases, such as rheumatic immune diseases, autoimmune nervous system diseases, digestive system diseases, blood system diseases, kidney diseases, organ transplantation, autoimmune skin diseases, metabolic diseases, and drug poisoning.[2] The goal of this therapy is to remove high-molecular-weight molecules, such as antibodies of systemic lupus erythematosus (SLE); IgA-containing immune complexes of Henoch–Schönlein purpura; circulating autoantibodies of Myasthenia gravis; IgG antibodies targeting the synaptic GluN1 subunit of the N-methyl-D-aspartate receptor (NMDAR) of NMDAR antibody encephalitis; albumin-bound toxins as well as unbound toxins, including aromatic amino acids, ammonia, endotoxin, indols, mercaptans, phenols, and other factors which may be responsible for hepatic coma of acute liver failure patient; and drug metabolites, cytokines, or other mediators of keratinocyte cytotoxicity of toxic epidermal necrolysis and so on. TPE is currently an accepted therapy for selected indications in children.[3]

Even the newborns can receive TPE treatment as long as they have suitable vascular access and filters.[4] Although principles of TPE are the same in adults and children, there are technical differences, such as establishment of vascular access and volume distribution. Risk of this therapy in children may be higher than that in adults.[5] Although this problem has been studied in a series of studies published over the last 30 years, most are data from adults.[6] The knowledge on TPE complications in children is still limited.[7,8] Accordingly, we conducted a retrospective study to investigate the complications of 1201 TPE procedures and discuss the safety of TPE in children.
2. Methods

2.1. Subjects

A series of hospitalized children who underwent at least 1 TPE procedure between January 2013 and July 2018 were enrolled. Studies were conducted with the approval of the Ethics Committee of West China Second University Hospital, Sichuan University and in accordance with the Declaration of Helsinki (1951) of the World Medical Association. Written informed consent was obtained from the children’s guardians before treatment.

2.2. TPE procedures

TPE was performed according to the blood purification standard operating procedure of TPE in China, which included establishing appropriate vascular access for corresponding age, plasma dose prescription, anticoagulation of the circuit, and so on. Vascular access was established using the Gambro temporary single-needle double-lumen catheter (specification: 6F, 8F, or 11F) through the femoral vein. Procedures were performed with the Gambro Prismaflex (Gambro Lundia AB, Lund, Sweden) or Fresenius machine and the corresponding set: TPE1000 and TPE2000, or P1 and P2. Almost all children had anticoagulation with low-molecular-weight heparin (LMWH) of 60 to 80 IU/kg, and few children with very poor coagulation function had no anticoagulation. The blood pump flow rate was 3 to 5 mL/kg/min and does not exceed 120 mL/min. Two plasma pumps (one pumping out the patient’s plasma and the other pumping in the alternative fresh frozen plasma [FFP]) were at the same speed, about 15% to 25% of the blood pump speed. Each TPE treatment will remove plasma which is approximately 5% of the child’s body weight and an equal amount of FFP was used as a replacement, the total amount does not exceed 3000 mL. An extra part of 100 to 150 mL plasma was needed to prime the extracorporeal circuit to prevent insufficient cycle capacity when the child weighs >10 kg. All children received intravenous calcium supplementation to prevent hypocalcemia caused by citrate in plasma preservation solutions, the dose was 2 mL of 10% calcium gluconate solution per each 250 mL FFP. If there are symptoms of hypocalcaemia such as perioral and limb numbness, an additional 10% calcium solutions, the dose was 2 mL of 10% calcium gluconate solution per each 250 mL FFP. If there are symptoms of hypocalcaemia such as perioral and limb numbness, an additional 10% calcium gluconate solution was given intravenous infusion of dexamethasone (0.5mg/kg, maximum 20mg) to prevent allergy.

2.3. Data collection

Clinical data such as age, sex, weight, clinical indications, and complications were collected by nurses in the blood purification unit for children.

2.4. Statistics

All data were processed using SPSS 21.0 statistical software (IBM, Armonk, NY). The counting data were expressed as the composition ratio, and Pearson χ² test was used for comparison. It was considered statistically significant when P < .05.

3. Results

3.1. Demographic characteristics

During 5 years, 1201 TPE treatments were performed on a total of 435 children, including 198 males (45.5%) and 237 females (54.5%). The median age was 9.16 years, with a range from 3 months to 15 years. Seventy-five patients (17.2%) were aged 3 months to 3 years, 67 patients (15.4%) were aged 3 to 6 years, and 293 patients (67.4%) were aged 6 to 15 years. The median body weight was 26 kg, with a range from 6.73 kg to 67 kg. Twenty-eight patients (6.4%) weighed ~10 kg, 245 patients (56.3%) weighed 10~30 kg, and 162 patients (37.2%) weighed 30~67 kg.

3.2. Indications of TPE

Indications for TPE are shown in Table 1. The top 4 clinical indications were acute poisoning, rheumatic diseases, kidney diseases, and neurologic diseases. The distribution of indications in children of different ages and weights is shown in Figures 1 and 2. The proportion of children with rheumatic diseases and kidney diseases was higher in the 6–15 year group and the 30–67 kg group.

3.3. Overall complications in children

Of total 1201 treatments, 152 procedures (12.7%) involved some complications. There were 90 procedures (7.5%) involving ≥2 complications during treatment. No death occurred. The overall incidence and type of complications are shown in Table 2. The most common complications were pruritus and urticaria (7%), followed by hypertension (1.92%) and hypotension (1.17%). Infection occurred in 3 patients. Two patients with anti-N-methyl-D-aspartate receptor encephalitis developed catheter-related infection (Staphylococcus aureus). One

Table 1

| Diagnosis                                | Procedure, n (%) | Cases, n (%) |
|------------------------------------------|------------------|--------------|
| Rheumatic disease                        | 374 (31.1%)      | 105 (24.1%)  |
| Systemic lupus erythematosus             | 323 (26.9%)      | 91 (20.9%)   |
| Juvenile dermatomyositis                 | 38 (3.2%)        | 10 (2.3%)    |
| ANCA-related vasculitis                  | 13 (1.1%)        | 4 (0.9%)     |
| Acute poisoning                          | 289 (24.1%)      | 146 (33.6%)  |
| Pesticide poisoning                      | 149 (12.4%)      | 72 (16.6%)   |
| Animal toxin poisoning                   | 93 (7.7%)        | 45 (10.3%)   |
| Plant toxin poisoning                    | 30 (2.5%)        | 19 (4.4%)    |
| Drug poisoning                           | 17 (1.4%)        | 10 (2.3%)    |
| Kidney disease                           | 181 (15.1%)      | 70 (16.1%)   |
| Henoch-Schönlein purpura nephritis       | 90 (7.5%)        | 33 (7.6%)    |
| Hemolytic uremic syndrome                | 37 (3.1%)        | 12 (2.8%)    |
| Rapidly progressive glomerulonephritis   | 54 (4.5%)        | 25 (5.7%)    |
| Nervous system disease                   | 181 (15.1%)      | 40 (9.2%)    |
| Anti-NMDA receptor encephalitis          | 141 (11.7%)      | 31 (7.1%)    |
| Optic neuritis                           | 18 (1.5%)        | 4 (0.9%)     |
| Guillain-Barré syndrome                  | 13 (1.1%)        | 3 (0.7%)     |
| Myasthenia gravis                        | 5 (0.4%)         | 1 (0.2%)     |
| Multiple sclerosis                       | 4 (0.3%)         | 1 (0.2%)     |
| Acute liver failure                      | 62 (5.2%)        | 23 (5.3%)    |
| Blood disease                            | 57 (4.7%)        | 19 (4.4%)    |
| Hemophagocytic syndrome                  | 45 (3.7%)        | 15 (3.4%)    |
| Macrophage activation syndrome           | 10 (0.8%)        | 3 (0.7%)     |
| Thrombotic thrombocytopenic purpura      | 2 (0.2%)         | 1 (0.2%)     |
| Sepsis                                   | 38 (3.2%)        | 26 (6.7%)    |
| Autoimmune thyroiditis                   | 11 (0.9%)        | 3 (0.7%)     |
| Toxic epidermal necrolysis               | 8 (0.7%)         | 3 (0.7%)     |

NMDA = N-methyl-D-aspartate.
child with SLE developed disseminated cryptococcosis neoformans infection.

Toxic epidermal necrolysis occurred in 3 patients with SLE. They were cured by methylprednisolone (15 mg/kg/day) pulse treatment and hemoperfusion. One child with anti-NMDA receptor encephalitis developed a severe allergic reaction during his 5th TPE treatment, which was relieved by oxygen inhalation, diphenhydramine, and subcutaneous injection of adrenaline.

3.4. Complications at different ages and weights

As shown in Table 3, the incidence of complications in children at different ages and weights was significantly different ($P<.05$). The complications were more common in the 6–15 year group and the 30–67 kg group. The incidence of pruritus and urticaria in children at different ages and weights was also significantly different ($P<.05$). The incidence of pruritus and urticaria was still more common in the 6–15 year group and the 30–67 kg group.
### Table 2
Type of complications of 1201 procedures in 435 children.

| Type                      | Procedure (%) |
|---------------------------|---------------|
| Incidence                 | 12.7%         |
| Replacement-related       |               |
| complications             |               |
| Pruritis                  | 85 (7.01%)    |
| Urticaria                 | 84 (7.00%)    |
| Hypertension              | 23 (1.92%)    |
| Hypotension               | 14 (1.17%)    |
| Chil                      | 9 (0.75%)     |
| Vomiting                  | 6 (0.50%)     |
| Abdominal pain            | 6 (0.50%)     |
| Cyanosis                  | 3 (0.20%)     |
| Toxic bullous epidermis   | 3 (0.25%)     |
| necrolysis                |               |
| Hemolysis                 | 2 (0.17%)     |
| Dyspnea                   | 2 (0.17%)     |
| Nausea                    | 2 (0.17%)     |
| Separator rupture         | 2 (0.17%)     |
| Fever                     | 1 (0.08%)     |
| Pharyngeal itching        | 1 (0.08%)     |
| Dizziness                 | 1 (0.08%)     |
| Tachycardia               | 0             |
| Headache                  | 0             |
| Anticoagulant-related     |               |
| complications             |               |
| Number of limb            | 3 (0.25%)     |
| Cloting of circuit        | 2 (0.17%)     |
| Vascular access-related   |               |
| complications             |               |
| Bleeding and hematoma     | 4 (0.33%)     |
| Access-related infection  | 3 (0.25%)     |
| Thrombosis                | 1 (0.08%)     |

### Table 3
Incidence and type of complications in 435 children at different ages and weights.

| Complications                  | Age, y | Weight, kg | 0–3 (n=75) | 3–6 (n=67) | 6–15 (n=293) | 0–10 (n=28) | 10–30 (n=245) | 30–67 (n=162) | Total |
|--------------------------------|--------|------------|------------|------------|--------------|-------------|---------------|---------------|-------|
| TPE procedures                 | 169    |            | 174 (14.5%)| 858 (71.4%)| 59 (4.9%)    | 669 (55.7%) | 473 (39.4%)   | 1201           |
| Procedures with complications  | 19     | 14         | 119        | 3          | 80           | 69          | 152           |                |
| Complication incidence        | 11.2%  | 8.0%       | 13.9%      | 5.1%       | 12.0%        | 14.6%       |               |                |
| Complication type, n (%)      |        |            |            |            |              |             |               |                |
| Pruritis                      | 10 (5.92%) | 6 (3.45%) | 69 (8.04%) | 1 (0.10%)  | 45 (6.73%)   | 40 (4.68%)  | 85 (7.07%)    |                |
| Urticaria                     | 9 (5.33%)  | 6 (3.45%) | 69 (8.04%) | 1 (0.10%)  | 50 (6.88%)   | 40 (4.68%)  | 84 (7.00%)    |                |
| Hypertension                  | 2 (1.18%) | 2 (1.15%) | 19 (2.21%) | 1 (0.10%)  | 12 (1.79%)   | 10 (1.12%)  | 23 (1.92%)    |                |
| Hypotension                   | 4 (2.37%) | 2 (1.15%) | 8 (0.93%)  | 1 (0.10%)  | 9 (1.35%)    | 4 (0.85%)   | 14 (1.17%)    |                |
| Chil                           | 1 (0.52%) | 3 (1.72%) | 5 (0.58%)  | 0          | 4 (0.60%)    | 5 (0.76%)   | 9 (0.75%)     |                |
| Vomiting                      | 1 (0.59%) | 0          | 5 (0.58%)  | 0          | 2 (0.30%)    | 4 (0.85%)   | 6 (0.50%)     |                |
| Abdominal pain                | 1 (0.59%) | 0          | 5 (0.58%)  | 1 (0.10%)  | 2 (0.30%)    | 3 (0.63%)   | 6 (0.50%)     |                |
| Bleeding and hematoma         | 2 (1.18%) | 0          | 2 (0.23%)  | 1 (0.10%)  | 1 (0.15%)    | 2 (0.42%)   | 4 (0.33%)     |                |
| Cyanosis                      | 0       | 0          | 3 (0.35%)  | 0          | 0            | 3 (0.63%)   | 3 (0.25%)     |                |
| Toxic epidermis necrolysis    | 1 (0.59%) | 0          | 2 (0.23%)  | 0          | 2 (0.30%)    | 1 (0.21%)   | 3 (0.25%)     |                |
| Numbness of limb              | 0       | 0          | 3 (0.35%)  | 0          | 1 (0.15%)    | 2 (0.42%)   | 3 (0.25%)     |                |
| Access-related infection      | 0       | 0          | 3 (0.35%)  | 0          | 1 (0.15%)    | 2 (0.42%)   | 3 (0.25%)     |                |
| Others                        | 1 (0.59%) | 2 (1.15%) | 11 (1.28%) | 0          | 10 (1.40%)   | 4 (0.85%)   | 14 (1.17%)    |                |

TPE = therapeutic plasma exchange.

The overall incidence of complications among different age groups was statistically significant ($\chi^2 = 4.370, P < 0.05$).

The overall incidence of complications between different body weights was statistically significant ($\chi^2 = 4.048, P < 0.05$).

Incidence of pruritus was statistically significant among different age groups ($\chi^2 = 4.530, P < 0.05$).

Incidence of urticaria was statistically significant among different age groups ($\chi^2 = 4.530, P < 0.05$).

Fibrinogen level before treatment (within 1 weeks before the first procedure) and after the last procedure (within 15 days) were collected in 179 children, albumin and globulin in 312 children. Level of fibrinogen and globulin decreased after treatment of therapeutic plasma exchange, whereas albumin shows no significant difference after the treatment (Table 5).

### 4. Discussion
In both adult and child studies, the incidence of TPE complications reported in the literature varies. In 2003, Norda et al[9] reported the registration study of TPE in Sweden. The incidence of TPE complications in 20,485 adults was 4.3% of all group. However, there was no significant difference in the incidence of hypertension and hypotension between different ages and weights ($P > 0.05$).

### 3.5. Analysis on diagnosis
We selected 5 most common indications (SLE, pesticide poisoning, anti-NMDA receptor encephalitis, rapidly progressive glomerulonephritis, severe purpura nephritis and liver dysfunction) to further analyze the incidence and type of complications. Table 4 shows that the incidence and type of TPE complications were also significantly different between indications. The incidence of complications and the incidence of urticaria were the highest in children with anti-NMDA receptor encephalitis ($P < 0.05$). Complications were rare in patients with other diseases, and thus, no statistical analysis was performed.

### 3.6. Effect on fibrinogen, albumin, and globulin
Fibrinogen level before treatment (within 1 weeks before the first procedure) and after the last procedure (within 15 days) were collected in 179 children, albumin and globulin in 312 children. Level of fibrinogen and globulin decreased after treatment of therapeutic plasma exchange, whereas albumin shows no significant difference after the treatment (Table 5).
reported in previous literature. Bambauer et al[20] compared the study showed that the incidence of TPE complications was children < 18 years (12.2% vs 9.9%). Witt et al[21] believed that the incidence of TPE complications in patients at different ages. The results showed that the incidence of TPE complications in children <18 years old was similar to that in adults aged 18 to 65 years (12.2% vs 9.9%). Witt et al[21] believed that the incidence of TPE complications in children was slightly lower than that in adults (4.0% vs 6.3%). The findings suggest that the incidence of TPE complications in adults and children is similar, and the incidence is not high. In the present study, 75 patients (17.2%) were aged from 3 months to 3 years. Therefore, TPE is even more convenient, and as well as lower incidence of heparin-induced thrombocytopenia. Besides, it is more convenient in the aspect of treatment protocols and techniques. There are few cases of bleeding in our study. LMWH was chosen as anticoagulant, as there are ways in which LMWH could be superior to unfractionated heparin: less thrombosis; less bleeding; more convenient, and as lower incidence of heparin-induced thrombocytopenia. Besides, it is more convenient in the aspect of monitoring compared to citrate solution. The dosage of LMWH in children is 50 to 80 U/kg and is given to them as the therapy starts.

We once expected more complication in the lower age group because of their low blood volume and immature organ function,[16] but that is not the fact. The study showed that the incidence of complications in the 6–15 year group was higher than that in the 0–3 year and 3–6 year groups, and the incidence of complications in the 30–60 kg group was still higher than that in the 0–10 kg group and 10–30 kg groups. Older age group appears higher complications, it may be related to higher dosage of plasma, the more plasma is used, the more susceptible to allergy.

The occurrence of TPE complications is influenced by several factors, including anticoagulant methods, types and volumes of replacement fluid, vascular access, diseases, and ways of plasma separation.[22] The present study further analyzed the incidence of complications in patients with different diseases. The results showed that patients with anti-NMDA receptor encephalitis had the highest incidence of complications. Carsten et al reported that the incidence of complications was the highest in patients with neurological diseases.[13] From the results of this study, children with nervous system undergoing plasma exchange should be treated with enhanced monitoring of adverse reactions. However, some studies have shown that the incidence of complications is higher in cryoglobulinemia and thrombocytopenic purpura patients compared with other diseases.[23,24] These findings may be due to selective bias in research subjects, heterogeneous treatment protocols and techniques. There are few cases of bleeding in our study. LMWH was chosen as anticoagulant, as there are ways in which LMWH could be superior to unfractionated heparin: less thrombosis; less bleeding; more convenient, and as well as lower incidence of heparin-induced thrombocytopenia. Besides, it is more convenient in the aspect of monitoring compared to citrate solution. The dosage of LMWH in children is 50 to 80 U/kg and is given to them as the therapy starts.

### Table 4

| Complication | SLE (n = 91) | Pesticide poisoning (n = 72) | Rapidly progressive glomerulonephritis (n = 25) | Anti-NMDA receptor encephalitis (n = 31) | Henoch-Schönlein purpura nephritis (n = 33) | Acute liver failure (n = 23) |
|--------------|-------------|-----------------------------|-----------------------------------------------|------------------------------------------|-------------------------------------------|----------------------------|
| TPE procedures | 323         | 149                         | 54                                            | 141                                      | 90                                        | 62                         |
| Procedures with complications | 39          | 18                          | 6                                             | 35                                      | 7                                         | 3                          |
| Complication incidence | 12.1%       | 12.1%                       | 11.1%                                         | 24.8%                                    | 7.8%                                      | 15.6%                      |
| Complication type | Pruritis | 17 (5.3%) | 11 (7.4%) | 2 (3.7%) | 26 (18.4%)* | 4 (4.4%) | 1 (1.6%) |
|                  | Urticaria   | 17 (5.3%) | 10 (6.7%) | 2 (3.7%) | 26 (18.4%)* | 4 (4.4%) | 1 (1.6%) |
|                  | Hypertension | 13 (4.0%) | 1 (0.7%) | 2 (3.7%) | 3 (2.1%) | 1 (1.6%) | 0 |
|                  | Hypothermia | 2 (0.6%) | 5 (3.4%) | 0 | 0 | 2 (3.2%) |
|                  | Chill       | 3 (0.9%) | 0 | 1 (1.9%) | 1 (0.7%) | 0 | 0 |
|                  | Vomiting    | 0 | 2 (1.3%) | 0 | 2 (1.4%) | 0 | 0 |
|                  | Abdominal pain | 2 (0.6%) | 1 (0.3%) | 0 | 0 | 1 (1.6%) |
|                  | Bleeding    | 1 (0.3%) | 0 | 0 | 1 (0.7%) | 0 | 0 |
|                  | Cyanosis    | 1 (0.3%) | 0 | 0 | 2 (1.4%) | 0 | 0 |
|                  | Toxic epidermis necrolysis | 2 (0.6%) | 0 | 0 | 0 | 0 |
|                  | Numbness of limb | 1 (0.3%) | 1 (0.7%) | 0 | 0 | 0 |
|                  | Access-related infection | 1 (0.3%) | 0 | 0 | 2 (1.4%) | 0 | 0 |

NMDA = N-methyl D-aspartate, TPE = therapeutic plasma exchange.

*P < .05
**P < .01

### Table 5

| Complication | Before TPE | After TPE | P |
|--------------|------------|-----------|---|
| Fibrinogen, mg/dL | 247.09 ± 121 | 223.21 ± 102 | <.05 |
| Albumin, g/L | 34.48 ± 9.44 | 35.4 ± 7.46 | >.05 |
| Globulin, g/L | 29.91 ± 7.41 | 25.26 ± 5.15 | <.01 |

TPE = therapeutic plasma exchange. Before TPE refers to the level before the first TPE procedure. After TPE refers to the level after the last TPE procedure.
hypocalcaemia (7.3%). Rodnitzky et al\[26\] reported the complications of 17 children with neurological disorders with 154 TPEs, including mild self-limiting toxicity-induced by citrate (7.8%), transient hypotension (2.6%), and amaurosis (1.3%). Gerard et al\[15\] reported the complications of 18 children with 280 TPEs, including blockage of vascular access (3.6%), bleeding (2.0%), disconnection (1.8%), mild hypotension (1.2%), urticaria (1.2%) and nausea, and vomiting (0.8%). Brunetta et al\[16\] reported 215 cases of TPE in children, including hypotension (6%), pain or paraesthesia (6%), transfusion reaction (6%), and facial oedema (1%). However, in the present study, the most common complications were pruritus and urticaria (7%), followed by hypertension (1.92%) and hypotension (1.17%).

Previous studies showed that FFP had significantly higher rates of adverse reactions than patients receiving other exchange fluids, such as 5% albumin\[23\]. FFP is associated with the anaphylactoid reaction. Allergic reactions to FFP are characterized by fever, rigors, urticaria, wheezing, and hypotension and can eventually develop into laryngospasm. We do not have large-capacity albumin for plasma exchange in China, and we believe that FFP is more complementary to normal body fluids and immune components than albumin. Therefore, we speculate that the high incidence of pruritus and urticaria is related to the use of FFP in the present study. Although most of the allergic reactions were urticaria and chills, Huestis et al\[23\] analyzed 42 patients who died of TPE and found that the potential life-threatening complications were still allergic reactions. At least 30 patients died using FFP. In the present study, 2 children suffered from toxic epidermal necrolysis, and 1 child went into anaphylactic shock; all 3 of these patients were forced to discontinue treatment. Therefore, when FFP is used as a replacement fluid, it is necessary to be highly alert to allergic reactions.

The incidence of TPE-induced infection varies greatly, and the pathogenesis of infection is still controversial. Wing et al\[30\] divided patients with acute glomerulonephritis who received routine treatment (hormones and immunosuppressive agents) into the TPE group and non-TPE group. The results showed that the TPE group had a higher incidence of infection. Aringer et al\[30\] also found that patients with SLE treated with TPE had an increased risk of severe infection. In the present study, one child with lupus nephritis who received routine treatment (glucocorticoid and immunosuppressants) developed disseminated cryptococcosis neoformans. From the above studies, we cannot exclude the possibility that the removal of immunoglobulins and complement resulted in an immunodeficient state, which impairs the patient’s ability to resist infection. Therefore, if severe infection occurs after TPE, the reasonable treatment is to restore normal immunoglobulin levels, which can be achieved by infusing immunoglobulin 100 to 400 mg/kg intravenously.

Previous studies have also shown that TPE may also induce shock, persistent arrhythmia, pulmonary embolism, vascular perforation, severe hemolysis, transfusion-related lung injury, and heparin-induced type II thrombocytopenia.\[31\]–\[33\] Although the above serious complications did not occur in the present study, they should be considered by clinicians and future researchers.

Limitations of the present study include its retrospective design and the fact that it is a single-center analysis. There may be selectivity bias of TPE inclusion criteria and disease type. However, the indications and procedures of TPE treatment in this study are consistent with the recommendations of the American Association for Plasma Separation and Exchange Guidelines in 2016.\[31\] In addition, the current study is one of the largest single-center cohorts published focused on children, and it adds to the scarce literature on TPE complications in children.

5. Conclusions

In conclusion, TPE is a safe blood purification treatment for children. Most of the complications of TPE are mild. The most common complications are pruritus and urticaria. However, serious complications, such as toxic epidermal necrosis and outbreak of infection, should be considered and prevented to avoid serious consequences.

Author contributions

Conceptualization: Jing Lu, Yuhong Tao.
Data curation: Jing Lu, Lijuan Zhang, Cheng Xia, Yuhong Tao.
Formal analysis: Yuhong Tao.
Investigation: Jing Lu, Lijuan Zhang, Cheng Xia.
Project administration: Yuhong Tao.
Supervision: Yuhong Tao.
Writing – original draft: Jing Lu, Yuhong Tao.
Writing – review & editing: Jing Lu, Yuhong Tao.

References

[1] Schwab PJ, Fahey JL. Treatment of Waldenstrom’s macroglobulinemia by plasmapheresis. N Engl J Med 1960;263:574–9.
[2] Schwartz J, Padmanabhan A, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the seventh special issue. J Clin Apher 2016;31:149–62.
[3] Wong EC, Balogun RA. Therapeutic apheresis in pediatrics: technique adjustments, indications and nonindications, a plasma exchange focus. J Clin Apher 2012;27:132–7.
[4] Vidal E, Garzotto F, Parolin M, et al. Therapeutic plasma exchange in neonates and infants: successful use of a miniaturized machine. Blood Purif 2017;44:100–5.
[5] Goldstein SL. Therapeutic apheresis in children: special considerations. Semin Dia 2012;25:163–70.
[6] Mokrzycki MH, Balogun RA. Therapeutic apheresis: a review of complications and recommendations for prevention and management. J Clin Apher 2011;26:243–8.
[7] Weiss PF, Klink AJ, Friedman DF, et al. Pediatric therapeutic plasma exchange indications and patterns of use in US children’s hospitals. J Clin Apher 2012;27:287–94.
[8] Meyer EK, Wong EC. Pediatric therapeutic apheresis: a critical appraisal of evidence. Transfus Med Rev 2016;30:217–22.
[9] Norda R, Stegmayr BG. Swedish Apheresis Group. Therapeutic apheresis in Sweden: update of epidemiology and adverse events. Transfus Apher Sci 2003;29:159–66.
[10] Sprenger KB, Rasche H, Franz HE. Membrane plasma separation: complications and monitoring. Artif Org 1984;8:360–3.
[11] Sutton DM, Nair RC, Rock G. Complications of plasma exchange. Transfusion 1989;29:124–7.
[12] Mokrzycki MH, Kaplan AA. Therapeutic plasma exchange: complications and management. Am J Kidney Dis 1994;23:817–27.
[13] Bramlage CP, Schroder K, Bramlage P, et al. Predictors of complications in therapeutic plasma exchange. J Clin Apher 2009;24:225–31.
[14] George JN, Terrell DR, Swisher KK, et al. Lessons learned from the Oklahoma thrombotic thrombocytopenic purpura-helemic ular syndrome registry. J Clin Apher 2008;23:129–37.
[15] Corrino G, Ojnnaga V, Giner T, et al. Therapeutic plasma exchange in children: one center’s experience. J Clin Apher 2017;32:494–500.
[16] Ozkale M, Erol I, Ozkale Y, et al. Overview of therapeutic plasma exchange in pediatric neurology: a single-center experience. Acta Neurol Belg 2018;118:431–8.
[17] Pagliuca P, Schmitt CP, Shroff R, et al. Indications, technique, and outcome of therapeutic apheresis in European pediatric nephrology units. Pediatr Nephrol 2015;30:103–11.
[18] De Silvestro G, Tison T, Vicarioto M, et al. The Italian Registry of Pediatric Therapeutic Apheresis: a report on activity during 2005. J Clin Apher 2009;24:1–5.

[19] Kara A, Turgut S, Çahi A, et al. Complications of therapeutic apheresis in children. Transfus Apher Sci 2013;48:375–6.

[20] Bambauer R, Jutzler GA, Filipippi H, et al. Hemofiltration and plasmapheresis in premature infants and newborns. Artif Organs 1988;12:20–6.

[21] Witt V, Stegmayr B, Ptak J, et al. World apheresis registry data from 2003 to 2007, the pediatric and adolescent side of the registry. Transfus Apher Sci 2008;39:255–60.

[22] Kaplan AA. Therapeutic plasma exchange: core curriculum 2008. Am J Kidney Dis 2008;52:1180–96.

[23] Shemin D, Briggs D, Greenan M. Complications of therapeutic plasma exchange: a prospective study of 1,727 procedures. J Clin Apher 2007;22:270–6.

[24] Rock G, Clark B, Sutton D. CAG, CAANThe Canadian apheresis registry. Transfus Apher Sci 2003;29:167–77.

[25] Basic-Jukic N, Kes P, Glavas-Boras S, et al. Complications of therapeutic plasma exchange: experience with 4837 treatments. Ther Apher Dial 2003;9:391–5.

[26] Michon B, Moghrabi A, Winikoff R, et al. Complications of apheresis in children. Transfusion 2007;47:1837–42.

[27] Brunetta Gavranic’ B, Basic-Jukic’ N, Kes P. Therapeutic plasma exchange—does age matter? A single-center study. Artif Organs 2016;40:786–92.

[28] Huestis DW. Mortality in therapeutic haemapheresis. Lancet 1983;1:1043.

[29] Wing EJ, Bruns FJ, Fraley DS, et al. Infectious complications with plasmapheresis in rapidly progressive glomerulonephritis. JAMA 1980;244:2423–6.

[30] Aringer M, Smolen JS, Graninger WB. Severe infections in plasmapheresis-treated systemic lupus erythematosus. Arthritis Rheum 1998;41:414–20.

[31] Szczeklik W, Wawrzycka K, Włudarczyk A, et al. Complications in patients treated with plasmapheresis in the intensive care unit. Anaesthesiol Intensive Ther 2013;45:7–13.

[32] Laird JH, Douglas K, Green R. Heparin-induced thrombocytopenia type II: a rare but significant complication of plasma exchange. J Clin Apher 2006;21:129–31.

[33] Mateen FJ, Gastineau D. Transfusion related acute lung injury (TRALI) after plasma exchange in myasthenic crisis. Neurocrit Care 2008;8:280–2.